Navigating Advances in NSCLC With EGFR PACC Mutations - Episode 2

EGFR PACC Mutation Identification Strategies in NSCLC

November 10, 2025

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center, Alexander I. Spira, MD, PhD

Panelists discuss how advanced genomic profiling techniques are vital for accurate detection of PACC mutations.

EP. 1: EGFR PACC Mutations in NSCLC

Now Viewing

EP. 2: EGFR PACC Mutation Identification Strategies in NSCLC

EP. 3: Current Treatment Approaches in NSCLC With PACC Mutations

EP. 4: Emerging Data on Firmonertinib for PACC Mutations in NSCLC

EP. 5: Data From the FURTHER Trial in NSCLC With EGFR PACC Mutations

EP. 6: Future Directions for NSCLC With PACC Mutations

Panelists discuss how comprehensive genomic profiling, including next-generation sequencing (NGS), remains critical for accurately identifying PACC mutations. They note that these variants can be underrecognized due to their rarity and structural complexity, making advanced molecular platforms essential.

Panelists discuss how RNA-based or hybrid-capture sequencing may enhance detection of compound or uncommon mutations, ensuring a complete molecular picture before treatment.

Panelists discuss how consistent communication between oncologists, pathologists, and molecular laboratories improves testing quality and facilitates timely identification, enabling patients to benefit from the most appropriate targeted therapies.